



## Integra LifeSciences to Present at Upcoming Healthcare Conferences

PLAINSBORO, N.J., Jan. 24, 2007 (PRIME NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it is scheduled to present at the Wachovia Small and Mid-Cap Healthcare Conference at the Langham Hotel in Boston on Tuesday, January 30, 2007 and at the Emerald Groundhog Day Investment Forum at the Radisson Plaza-Warwick Hotel in Philadelphia on Thursday, February 1, 2007.

The Wachovia presentation will be delivered by Maureen Bellantoni, Executive Vice President and Chief Financial Officer of Integra. A live webcast of this presentation can be accessed through a link provided on the home page of the Investor Relations section of Integra's website at <http://www.integra-LS.com>. Additionally, a replay of the webcast will be available through Monday, February 12, 2007.

The Emerald presentation will be delivered by Stuart Essig, President and Chief Executive Officer of Integra. This presentation will not be available via webcast.

Each of the presentations will provide an overview of Integra's operations, with a focus on currently marketed products, sales distribution channels and product pipeline, recent financial history, and Integra's overall business strategy for growth.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets implants for surgery and a broad line of medical and surgical instruments. The primary applications for our products are neurosurgery, extremity reconstruction and orthopedics. Integra is a world leader in regenerative medicine. Our products provide cost effective solutions that improve the quality of life for patients. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. Please visit our website at <http://www.integra-LS.com>.

Statements made at the upcoming conference may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2005 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation  
John B. Henneman, III, Executive Vice President, Chief  
Administrative Officer  
(609) 936-2481  
[jhenneman@Integra-LS.com](mailto:jhenneman@Integra-LS.com)  
John Bostjancic, Vice President, Corporate Development and  
Investor Relations  
(609) 936-2239  
[jbostjancic@integra-LS.com](mailto:jbostjancic@integra-LS.com)